Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Receivables (2016 - 2021)

Historic Receivables for Agios Pharmaceuticals (AGIO) over the last 9 years, with Q4 2022 value amounting to $2.2 million.

  • Agios Pharmaceuticals' Receivables fell 4961.17% to $2.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $2.2 million, marking a year-over-year decrease of 4961.17%. This contributed to the annual value of $2.2 million for FY2022, which is 4961.17% down from last year.
  • Agios Pharmaceuticals' Receivables amounted to $2.2 million in Q4 2022, which was down 4961.17% from $4.4 million recorded in Q4 2021.
  • Agios Pharmaceuticals' Receivables' 5-year high stood at $38.7 million during Q2 2018, with a 5-year trough of $2.2 million in Q4 2022.
  • For the 5-year period, Agios Pharmaceuticals' Receivables averaged around $11.7 million, with its median value being $8.9 million (2019).
  • As far as peak fluctuations go, Agios Pharmaceuticals' Receivables soared by 58763.57% in 2018, and later crashed by 7497.93% in 2019.
  • Agios Pharmaceuticals' Receivables (Quarter) stood at $7.5 million in 2018, then skyrocketed by 39.17% to $10.5 million in 2019, then soared by 103.25% to $21.3 million in 2020, then plummeted by 79.47% to $4.4 million in 2021, then crashed by 49.61% to $2.2 million in 2022.
  • Its Receivables stands at $2.2 million for Q4 2022, versus $4.4 million for Q4 2021 and $21.3 million for Q3 2020.